Buprenorphine extended-release injection (Sublocade®)

On Nov 30, 2017, US Food and Drug Administration (FDA) has granted approval to Indivior Inc. for marketing the first once-monthly buprenorphine injection for moderate-to-severe opioid use disorder. The brand name is Sublocade. As you know, buprenorphine has been available in three forms for the treatment of opioid use disorder: 1. A sublingual formulation by…